EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Andrew Blauvelt, Mark Lebwohl, Richard G Langley, Katelyn Rowland, Ya-Wen Yang, Daphne Chan, Megan Miller, Yin You, Jenny Yu, Diamant Thaҫi, Peter Foley, Kim A Papp

Journal of the American Academy of Dermatology · 2023-08 · 89 (2) · 274-282

DOI: 10.1016/j.jaad.2023.03.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2023-08. Verfasst von Andrew Blauvelt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Dermatologic Agents, Psoriasis, Skin Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Malignancy risk surveillance among patients receiving long-term immunomodulatory psoriasis treatments remains an important safety objective. OBJECTIVE: To report malignancy rates in patients with moderate-to-severe psoriasis treated with guselkumab for up to 5 years versus general and psoriasis patient populations. METHODS: Cumulative rates of malignancies/100 patient-years (PY) were evaluated in 1721 guselkumab-treated patients from VOYAGE 1 and 2. Malignancy rates (excluding nonmelanoma skin cancer [NMSC]) were compared with rates in the Psoriasis Longitudinal Assessment and Registry. Standardized incidence ratios comparing malignancy rates (excluding NMSC and cervical cancer in situ) between guselkumab-treated patients and the general US population using Surveillance, Epidemiology, and End Results data were calculated, adjusting for age, sex, and race. RESULTS: Of 1721 guselkumab-treated patients (>7100 PY), 24 had NMSC (0.34/100PY; basal:squamous cell carcinoma ratio, 2.2:1), and 32 had malignancies excluding NMSC (0.45/100PY). For comparison, the malignancy rate excluding NMSC was 0.68/100PY in the Psoriasis Longitudinal Assessment and Registry. Malignancy rates (excluding NMSC/cervical cancer in situ) in guselkumab-treated patients were consistent with those expected in the general US population (standardized incidence ratio = 0.93). LIMITATIONS: Inherent imprecision in determining malignancy rates. CONCLUSIONS: In patients treated with guselkumab for up to 5 years, malignancy rates were low and generally consistent with rates in general and psoriasis patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsDermatologic AgentsPsoriasisSkin NeoplasmsFemaleHumansAdalimumabFollow-Up StudiesSeverity of Illness IndexTreatment OutcomeDouble-Blind MethodAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

guselkumabmalignancynonmelanoma skin cancerpsoriasissafetytumor

Substanzen

AdalimumabDermatologic AgentsguselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Division of Clinical Dermatology & Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Immunology, Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania.
  • Janssen Research & Development, LLC, Spring House, Pennsylvania.

Förderung

  • Janssen Research and Development LLC

Zitieren

APA

Blauvelt, A., Lebwohl, M., Langley, R. G., Rowland, K., Yang, Y. W., Chan, D., Miller, M., You, Y., Yu, J., Thaҫi, D., Foley, P., & Papp, K. A. (2023). Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 89(2), 274-282. https://doi.org/10.1016/j.jaad.2023.03.035

Vancouver

Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, et al. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology. 2023;89(2):274-282. doi:10.1016/j.jaad.2023.03.035

BibTeX
@article{Blauvelt2023,
  author = {Blauvelt, Andrew and Lebwohl, Mark and Langley, Richard G and Rowland, Katelyn and Yang, Ya-Wen and Chan, Daphne and Miller, Megan and You, Yin and Yu, Jenny and Thaҫi, Diamant and Foley, Peter and Papp, Kim A},
  title = {Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials},
  journal = {Journal of the American Academy of Dermatology},
  year = {2023},
  volume = {89},
  number = {2},
  pages = {274--282},
  doi = {10.1016/j.jaad.2023.03.035}
}
Kostenlos starten →